Liminatus Pharma LLC(LIMN)
0.1224-0.0253-17.13%
行情数据延迟15分钟
- 最新
- 推荐
暂无内容公司概况
公司名称Liminatus Pharma LLC所属市场NASDAQ成立日期- -员工人数- -办公地址- -公司网址- -邮政编码- -联系电话- -联系传真- -公司概况Liminatus Pharma, Inc.是一家特拉华州公司，成立于2022年11月23日。Liminatus是一家临床前阶段的生物制药公司，开发新型的免疫调节癌症疗法。公司候选IBA101，是一种人源化抗CD47单抗。下一代CD47检查点抑制剂的初步适应症预计为包括非小细胞肺癌在内的晚期实体癌患者。作为一家全球领先的生物制药公司，该公司的愿景是为癌症患者开发一系列广泛的变革性疗法。- 07-06Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]超过5%披露Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 07-06Form 8-K - Current report重要事件披露Form 8-K - Current report
- 06-24Form S-1 - General form for registration of securities under the Securities Act of 1933招股说明书Form S-1 - General form for registration of securities under the Securities Act of 1933
- 06-03Form 8-K - Current report重要事件披露Form 8-K - Current report
- 05-28Form 8-K - Current report重要事件披露Form 8-K - Current report
- 05-20Form 8-K - Current report重要事件披露Form 8-K - Current report
- 05-15Form 10-Q - Quarterly report [Sections 13 or 15(d)]季度报告Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 03-31Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]年度报告Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 03-05Form 8-K - Current report重要事件披露Form 8-K - Current report
- 02-18Form 8-K - Current report重要事件披露Form 8-K - Current report
- 02-12Form CORRESP - CorrespondenceSEC问询函Form CORRESP - Correspondence
- 02-12Form CORRESP - CorrespondenceSEC问询函Form CORRESP - Correspondence
- 02-11Form S-1 - General form for registration of securities under the Securities Act of 1933招股说明书Form S-1 - General form for registration of securities under the Securities Act of 1933
- 02-09Form 8-K - Current report重要事件披露Form 8-K - Current report
- 01-26Form 8-K - Current report重要事件披露Form 8-K - Current report
- 分时
- 5日
- 日
- 周
- 月
数据加载中...
最高
0.1319
今开
0.1224
量比
0.24
最低
0.1150
昨收
0.1477
换手率
72.59%